Phosphotyrosine profiling of in vivo signaling changes in erlotinib-treated glioblastoma flank xenografts

ABSTRACT: Mass spectrometry-based quantitative proteomics profiling of in vivo signaling changes in 16 GMB xenograft tumors treated with vehicle and erlotinib (5 mg/kg, 33 mg/kg, 100 mg/kg).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

DISEASE(S): Brain Glioblastoma Multiforme

SUBMITTER: Kristina Bennet Emdal  

LAB HEAD: Forest White

PROVIDER: PXD006769 | Pride | 2018-11-06

REPOSITORIES: Pride